ImmunoPrecise Antibodies (NASDAQ: IPA) has developed a new class of GLP-1 therapies using artificial intelligence through its proprietary LENSai™ platform. The AI-designed therapeutics aim to improve current diabetes and obesity treatments by enhancing efficacy, safety, and patient satisfaction.
The company’s innovation focuses on creating GLP-1-like alternatives with potential advantages including increased patentability, extended…
Article Source
https://www.stocktitan.net/news/IPA/ipa-immuno-precise-antibodies-pioneers-ai-designed-glp-1-therapies-a-0hjutcyoqaht.html
